Comments over the weekend by FDA chief Martin Makary suggest the agency views Novavax’s updated COVID shot as a “new product” ...

The deal, which has been in the works for months, hands the German pharmaceutical company two approved drugs for rare tumors.

Sen. Bill Cassidy’s report calls on Congress to improve the transparency of the drug discount program in a move praised by ...

Interim results from a study in China suggest ivonescimab may reduce the risk of death versus Keytruda, but the difference ...

Currently under review in the U.S. for a rare genetic disorder, the drug is seen by some investors as critical to Biohaven’s ...

The company reiterated its financial outlook for the year but is struggling to predict the likely impact of pharmaceutical ...

Repertoire Immune Medicines will get $35 million upfront, and possibly $730 million more, in a deal to help Roche’s Genentech ...

The biotech is using AI and a trove of health data to better understand why certain conditions progress and intervene ...

The company is looking to the highly anticipated launch of a closely watched HIV medicine to offset weakening demand for ...

The CRISPR company is laying off about a third of its employees and stopping work on an experimental lupus treatment in a bid ...

An ivonescimab-chemotherapy combination succeeded in a study in China. Elsewhere, the FDA asked Novavax for more COVID ...

Net sales of Cobenfy, whose success is imperative for Bristol Myers, totaled $27 million in the first quarter, handily ...